Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Travere Therapeutics, Inc. (TVTX) provides access to the company’s official disclosures as a Nasdaq‑listed biopharmaceutical issuer focused on rare kidney, liver and metabolic diseases. Travere files periodic and current reports with the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934.
Recent Form 8‑K filings document press releases announcing quarterly and preliminary annual financial results, including net product sales and other financial metrics, as well as broader corporate updates. These reports specify when information is being furnished rather than filed for purposes of Section 18 of the Exchange Act and clarify that such information is not automatically incorporated by reference into registration statements unless expressly stated.
Travere also uses Form 8‑K to report material regulatory developments. For example, the company has filed 8‑Ks describing FDA communications on the supplemental New Drug Application (sNDA) for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS), including the decision that an advisory committee meeting was no longer needed and confirmation of the Prescription Drug User Fee Act (PDUFA) target action date. Another 8‑K notes the FDA’s extension of the review timeline after the company submitted additional information characterized as a Major Amendment.
Through this page, users can review Travere’s financial reporting (10‑K and 10‑Q when available), current reports on significant events (8‑K), and other disclosures that describe the company’s clinical programs, commercial activities, risk factors and capital structure. Stock Titan enhances these filings with AI‑powered summaries that highlight key points in lengthy documents, helping readers quickly understand topics such as revenue drivers, R&D spending, regulatory interactions and forward‑looking statements. Real‑time updates from EDGAR and access to insider and executive transaction reports, when filed on forms such as Form 4, allow investors to monitor how management actions and regulatory events intersect with Travere’s strategy in rare diseases.
Travere Therapeutics insider plans additional share sale under Rule 144. A person identified as Eric M. Dube has filed to sell 100,087 shares of common stock of Travere Therapeutics through Fidelity Brokerage Services on NASDAQ, with an approximate sale date of 02/03/2026 and an aggregate market value of $3,289,859.69. The filing notes 89,472,327 common shares outstanding.
The 100,087 shares were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 02/02/2026. Over the prior three months, the same seller completed two sales of Travere common stock totaling 8,135 and 51,865 shares, generating gross proceeds of $244,153.28 and $1,560,982.50.
A Rule 144 notice covers a planned sale of 12,446 shares of common stock of the issuer on 02/03/2026 through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of $409,100.02. The filing reports that 89,472,327 shares of this class were outstanding.
The seller, William E. Rote, acquired these 12,446 shares on 02/02/2026 via restricted stock vesting from the issuer as compensation. The notice also discloses that he sold 60,000 common shares on 12/24/2025 for gross proceeds of $2,406,178.52.
Travere Therapeutics CEO Eric M. Dube reported planned option exercises and related stock sales under a Rule 10b5-1 trading plan adopted on June 16, 2025. On January 23 and January 27, 2026, he exercised employee stock options for a total of 60,000 shares of common stock at an exercise price of
Eric M. Dube has filed a notice of proposed sale of TVTX common stock under Rule 144. The filing covers 51,865 common shares to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of 1,560,982.50. The issuer has 89,472,327 shares of common stock outstanding. The shares to be sold were acquired on 01/27/2026 through the cash exercise of an option originally granted on 01/31/2020.
The notice also lists prior sales of the issuer’s common stock by Dube during the past three months. These include 92,872 shares sold on 10/28/2025 for 2,821,217.14, 27,128 shares sold on 10/29/2025 for 817,045.37, and 8,135 shares sold on 01/23/2026 for 244,153.28. By signing, the seller represents that he is not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
Travere Therapeutics insider plans another stock sale. A person identified in the filing plans to sell 8,135 shares of Travere Therapeutics common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of 244,153.28, when 89,472,327 shares were outstanding as of the notice. The shares were acquired on 01/23/2026 via an option granted on 01/31/2020 and paid for in cash.
Over the prior three months, Eric M. Dube at a San Diego address sold 92,872 Travere common shares on 10/28/2025 for 2,821,217.14 and 27,128 shares on 10/29/2025 for 817,045.37. The signer represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Travere Therapeutics Chief Legal Officer Elizabeth E. Reed reported an option exercise and share sale in Travere Therapeutics, Inc. common stock. On January 20, 2026, she exercised 10,000 employee stock options at an exercise price of $19.08 per share and received 10,000 shares of common stock.
That same day, she sold 10,000 shares of Travere common stock at a weighted average price of $27.3420 per share under a Rule 10b5-1(c) trading plan adopted on June 16, 2025, tied to a stock option grant from January 4, 2017 that expires on January 4, 2027. After these transactions, she directly beneficially owned 90,270 shares of common stock, which include 392 shares acquired through the 2017 Employee Stock Purchase Plan, and held 30,000 employee stock options that are fully vested and exercisable.
A holder of TVTX common stock has filed a notice to sell 10,000 shares under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an indicated aggregate market value of $273,420.00. The filing shows 89,472,327 shares of this class outstanding.
The 10,000 shares were acquired from the issuer on 01/20/2026 through a stock option exercise paid in cash on the same date, and are the securities covered by this planned sale.
Travere Therapeutics reported that the U.S. FDA has extended the review timeline for its supplemental New Drug Application for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new PDUFA target action date is April 13, 2026, following the company’s recent submission of additional information requested by the FDA to further characterize FILSPARI’s clinical benefit.
The FDA classified the submission as a Major Amendment to the application and extended the review period accordingly, and has not requested any new safety or manufacturing data. If ultimately approved, FILSPARI would be the first medication indicated for FSGS, a rare kidney disease with no FDA-approved pharmacologic therapies, and would add to FILSPARI’s existing full approvals in the U.S. and EU for slowing kidney function decline in adults with IgA nephropathy.
Travere Therapeutics, Inc. filed a current report stating that on January 12, 2026 it issued a press release with certain preliminary financial results for the fourth quarter and full year ended December 31, 2025. The company is furnishing this information under a section that keeps the press release and related details from being treated as formally filed or automatically incorporated into other regulatory documents. The press release is included as Exhibit 99.1, and the report also includes a cover page interactive data file as Exhibit 104.
Travere Therapeutics Inc. received a Schedule 13G filing showing that FMR LLC and Abigail P. Johnson beneficially own 10,567,302.78 shares of its common stock, representing 11.7% of the class as of 12/31/2025. FMR LLC reports sole voting power over 10,224,163.76 shares and sole dispositive power over 10,567,302.78 shares, while Abigail P. Johnson reports sole dispositive power over the same 10,567,302.78 shares.
The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Travere Therapeutics. It also notes that one or more other persons may have the right to receive dividends or proceeds from these shares, but no single such person holds more than five percent of the outstanding common stock.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
